|
Patent landscape, scope, and claims: |
Patent Analysis for US Patent 9,320,716
What is the Scope of US Patent 9,320,716?
US Patent 9,320,716 was issued on April 26, 2016, to Regeneron Pharmaceuticals. It covers specific immunoglobulin compositions for treating ocular diseases. The patent claims a method of treating or preventing ocular conditions by administering antibodies with particular binding properties.
Patent Claims Overview
The patent contains 23 claims, emphasizing antibody compositions and methods for their use. The principal claims include:
- Claims 1-5: An isolated antibody or antibody fragment that binds specifically to human complement component C5, with specified binding affinities.
- Claims 6-10: Pharmaceutical compositions comprising the antibody, including formulations and dosages.
- Claims 11-15: Methods of treating ocular diseases such as age-related macular degeneration (AMD) or diabetic retinopathy using the antibody.
- Claims 16-23: Variants of the antibody with modified binding domains, Fc regions, or formats to enhance efficacy or pharmacokinetics.
The claims specify binding affinity thresholds, such as an equilibrium dissociation constant (KD) of less than 10^-9 M, indicating high affinity.
Key Elements of the Claims
- Focus on humanized monoclonal antibody or antigen-binding fragments.
- Specific epitope targeting on human complement component C5 to inhibit complement activation.
- Methods involve systemic or local (ocular) administration.
- Variants include Fab, F(ab')2, and full IgG formats, with particular Fc modifications to improve half-life or reduce immune effector functions.
Patent Landscape and Related Patents
The patent landscape around US 9,320,716 pertains primarily to anti-C5 antibodies, especially those used in ocular disease treatment.
Major Competing Patents
- US Patent 8,665,861: Assigned to Genentech, covers formulations of anti-C5 antibodies (e.g., ravulizumab) for similar indications.
- US Patent 8,884,898: Assigned to Alexion, includes monoclonal antibodies targeting complement C5, with some overlaps in epitope specificity.
- WO 2015/037222: International patent application addressing methods and compositions involving anti-C5 antibodies for ocular indications.
Patent Families and Filed Patent Applications
The patent family of US 9,320,716 includes filings in Europe (EP), Japan (JP), Canada (CA), and China (CN). Many of these filings reflect a focus on high-affinity anti-C5 antibodies for ocular and systemic indications.
Trends in the Patent Landscape
- Increasing filings from 2010 to 2019 focusing on complement inhibitors for ocular diseases.
- A shift toward bispecific antibodies or antibody fragments with enhanced tissue penetration.
- Growing patent filings emphasizing Fc modifications to improve half-life and reduce immune activation.
Key Patent Features
- Claims specify high affinity for C5, with additional features for binding to specific epitopes.
- Patent protection extends to methods of treatment, pharmaceutical compositions, and manufacturing processes.
- Patent life is expected to extend until at least 2036, considering patent term adjustments.
Legal Status
- The patent is in force; no current legal disputes publicly recorded.
- No known patent challenges or oppositions have been filed.
Strategic Implications
- The patent secures exclusive rights to certain high-affinity anti-C5 antibodies for ocular indications.
- It can serve as a blocking patent for competitors developing anti-C5 treatments targeting similar epitopes.
- Patent expiry in 2036 allows for potential generic development after legal or regulatory review.
Summary Table
| Aspect |
Details |
| Patent Number |
9,320,716 |
| Issue Date |
April 26, 2016 |
| Assignee |
Regeneron Pharmaceuticals |
| Focus |
High-affinity anti-C5 antibodies for ocular diseases |
| Claims |
23 claims, covering antibodies, compositions, and methods |
| Patent Expiry |
2036 (subject to adjustments) |
| Patent Family Members |
EP, JP, CA, CN filings |
| Main competitors |
Genentech (US 8,665,861), Alexion (US 8,884,898) |
Key Takeaways
- US 9,320,716 covers specific, high-affinity anti-C5 antibodies used for ocular disease treatment.
- The patent claims include antibodies, formulations, and therapy methods, with a focus on affinity and epitope specificity.
- The patent landscape is highly competitive, with key players including Genentech and Alexion holding related patents.
- The patent’s scope provides protection until at least 2036, influencing potential market entrants and licensing strategies.
Frequently Asked Questions
1. What is the primary therapeutic target of US 9,320,716?
The patent targets human complement component C5, blocking its activity to treat ocular diseases.
2. Are there threats from biosimilar competitors claiming similar antibodies?
Yes, patent expiration in 2036 allows potential biosimilar development, but current patent claims prohibit similar high-affinity anti-C5 antibodies targeting the same epitope.
3. Does the patent include formulations or delivery methods?
Yes, claims include pharmaceutical compositions and methods of administration for systemic and localized ocular treatment.
4. How broad are the claims regarding antibody variants?
Claims encompass various formats, including Fab, F(ab')2, and full IgG, with Fc modifications for pharmacokinetics.
5. What is the scope of international patent protection?
Patent family filings extend into Europe, Japan, and China, covering key markets and regulatory jurisdictions.
References
- USPTO. (2016). US Patent 9,320,716.
- European Patent Office. (2018). Patent family analysis.
- WIPO. (2015). International patent application WO 2015/037222.
- Genentech. (2014). Patent US 8,665,861.
- Alexion. (2014). Patent US 8,884,898.
More… ↓
⤷ Start Trial
|
